Skip to main content

Table 1 Patient characteristics

From: Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patients

  All patients (n = 21) Responders (n = 7) Non-responders (n = 14) P- value
Gender, n (%)
 Male 11 (52) 5 (71) 6 (43) 0.36
 Female 10 (48) 2 (29) 8 (57)  
Age, years (range)
 Median 52 (21–70) 53 (35–65) 48 (21–70) 0.66
WHO performance status, n (%)
 0 10 (48) 2 (29) 8 (57) 0.42
 1 9 (43) 4 (57) 5 (36)  
 2 2 (9) 1 (14) 1 (7)
Secondary glioblastoma, n (%)
 Yes 1 (5) 0 1 (7) 1.00
 No 20 (95) 7 (100) 13 (93)  
Standard glioblastoma therapy, n (%)
 Yes 20 (95) 7 (100) 13 (93) 1.00
 No 1 (5) 0 1 (7)  
Prior lines of chemotherapy, n (%)
 1 18 (86) 7 (100) 11 (79) 0.52
 2 3 (14) 0 3 (21)  
Tumor size, cm2 (range)
 Median 9 (1–28) 11 (4–28) 8 (1–16) 0.65
Multifocal disease, n (%)
 Yes 2 (10) 0 2 (14) 0.53
 No 19 (91) 7 (100) 12 (86)  
Corticosteroid use, n (%)a
 Yes 14 (67) 3 (43) 11 (79) 0.16
 No 7 (33) 4 (57) 3 (21)  
Neurocognitive deficit, n (%)
 Yes 8 (38) 3 (43) 4 (29) 0.35
 No 13 (62) 4 (57) 10 (71)  
Primary sample, before bevacizumab, n (%)
 Initial glioblastoma diagnosis 10 (48) 3 (43) 7 (50) 1.00
 Relapse surgery prior to bevacizumab 11 (52) 4 (57) 7 (50)  
Time duration from relapse surgery (after bevacizumab), months
 to initiation of standard therapy, median 17 17 17 0.76
 to last bevacizumab administration, median 2 2 2 0.26
Number of bevacizumab treatment cyclesb
 Median 6 8 6 0.08
Bevacizumab combination therapy, n (%)
 Irinotecan 17 (81) 6 (86) 11 (79) 1.00
 Irinotecan and cetuximab 4 (19) 1 (14) 3 (21)  
Response, n (%)
 Response (CR + PR) 7 (33) 7 (100) 0  
 Stable disease 10 (48) 0 10 (71)
 Progressive disease 4 (19) 0 4 (29)
Progression-free survival, months
  Median 5.4 10.8 3.9 0.02
Overall survival, months
  Median 10.8 14.3 8.6 0.16
  1. Abbreviations: CR complete response, PR partial response
  2. a Prednisolone >10 mg
  3. b Two bevacizumab combination treatments (28 days) defined one treatment cycle